NASDAQ: CLRBa clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31,and provided a corporate update. Fourth Quarter and Recent Corporate Highlights. View differences made from one year to another to evaluate Cellectar Biosciences, Inc.
Shares of Aclaris Therapeutics Inc. Seborrhoeic keratoses, or SK, are one of the most common noncancerous skin growths that some people get as they age. These skin growths can be removed by cryotherapy, excision or laser treatment.
After a single As a result of these favorable outcomes, the company has expanded this cohort to include up to 30 additional patients. All DLBCL patients enrolled are required to have relapsed or refractory disease to multidrug chemotherapy regimens containing rituximab and an anthracycline.
As filed with the Securities and Exchange Commission on July 17, Registration No. State or other jurisdiction of.
This particular bit of news leaves your friend Doc Gumshoe shaking his head in puzzlement. To wit, in the US it is expected that there will be a substantial shortage of physicians in the upcoming years. The American Association of Medical Colleges predicts that this shortage may reach aboutphysicians by the year […].
The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors. This platform takes advantage of a metabolic pathway utilized by all tumor cell types in all cell cycle stages. In addition, PDCs can be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively delivered.
The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors. This platform takes advantage of a metabolic pathway utilized by all tumor cell types in all cell cycle stages. In addition, PDCs can be conjugated to molecules in numerous ways, thereby increasing the types of molecules selectively delivered. Cellectar believes the PDC platform holds potential for the discovery and development of the next generation of cancer-targeting agents.
This headline-only article is meant to show you why a stock is movingthe most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Proour flagship platform for fast, actionable information that promotes faster, smarter trading. Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.
Nasdaq:CLRBa clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced today that, after review of the company's investigational new drug IND application, the U. As a result of this classification, the FDA has advised Cellectar that it will need to submit a new investigational application for the combination product prior to initiating its planned proof-of-concept trial in breast cancer surgery. Current labeling for such devices is limited to FDA approved applications such as cardiac, circulatory, hepatic and ophthalmic conditions," said Dr.